Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8542898 | 1.00 | DRD4 (0.34) | DRD4DRD2NPC1RAB9ACTNNB1 | |
| SCHEMBL30915237 | 0.86 | LMNA (0.34) | NPC1CTNNB1 | |
| SCHEMBL6763775 | 0.86 | LMNA (0.34) | NPC1CTNNB1 | |
| SCHEMBL30915236 | 0.86 | LMNA (0.34) | NPC1CTNNB1 | |
| SCHEMBL1457093 | 0.86 | LMNA (0.34) | NPC1CTNNB1 | |
| SCHEMBL3364797 | 0.86 | LMNA (0.34) | NPC1CTNNB1 | |
| SCHEMBL8346622 | 0.84 | SGMS2 (0.40) | — | |
| SCHEMBL6559875 | 0.83 | ALDH1A1 (0.32) | CTNNB1WNT3A | |
| SCHEMBL6278805 | 0.83 | NISCH (0.36) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6979192 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670171-B2 | Process for preparing fluoxastrobin | ARYSTA LIFESCIENCE CORP (JP) | 2017-06-06 | — | — | US | disclosed |
| US-20160237047-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | ARYSTA LIFESCIENCE CORP (JP) | 2016-08-18 | — | — | US | disclosed |
| US-9193698-B2 | Process for preparing fluoxastrobin | ADVINUS THERAPEUTICS, LTD. (IN) | 2015-11-24 | — | — | US | disclosed |
| US-20150011753-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | ARYSTA LIFESCIENCE CORPORATION (JP) | 2015-01-08 | — | — | US | disclosed |
| US-5883250-A | ARYL SUBSTITUTED COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-03-16 | — | — | US | disclosed |
| US-5679676-A | Substituted azadioxacycloalkenes and their use as fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1997-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237047-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | CYP4X1, MB, HAO2 | DRD4 1567/4885DRD2 2131/4885NPC1 4442/4885 |
| US-20150011753-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | CYP4X1, MB, HAO2 | DRD4 1567/4885DRD2 2131/4885NPC1 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.